Drug Trial Radar · NCT04808531
NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers
Last checked: Nov 19, 2026Latest source record: Apr 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
360
Planned (sponsor's estimate)
Start
Nov 2023
Primary completion
Feb 2024
Study completion Jun 2024
Sponsor
- Lead sponsor
- Medlab ClinicalIndustry
- Sponsor type
- Industry
- Collaborators
- Emerald Clinical Inc.; WriteSource Medical Pty Ltd
- First posted
- Mar 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-centre, long term, double blind, clinical protocol for NanaBis™ as a monotherapy treatment in participants 18-75 years of age with cancer related pain.
Conditions
- Cancer Related Pain
Interventions
NanaBis™Drug
NanaBis™ is a nanoparticle water soluble equimolar solution of d9-THC \& CBD. One dose is equivalent to 2 actuations of the pump delivering 280 µL volume containing 2.5 mg d9-THC and 2.5 mg CBD
Oxycodone CRDrug
Oxycodone CR tablet is an opioid agonist supplied in 10 mg, 15 mg, 20 mg, 30 mg,40 mg, 60 mg and 80 mg tablets for oral administration. The tablet strengths describe the amount of oxycodone per tablet as the hydrochloride salt.
Placebo SprayDrug
Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.
Placebo TabletDrug
Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.
Oxycodone IRDrug
Oxycodone immediate release (IR) tablet or capsule or oral solution used as breakthrough analgesia.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Significant changes in responders with NanaBis™ spray over placebo (p<0.05)Time frame: 6 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.